A Bill to set a target for the number of glioblastoma patients who take part in clinical trials each year; to require training for medical oncologists to include training relating to brain cancers; to provide that any drug that has been licensed for use on tumours must be trialled on people with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS, including a requirement that each such team must include a medical oncologist; to require manufacturers of drugs licensed to treat tumours to make those drugs available in specified circumstances for clinical trials relating to brain tumours; and for connected purposes.
House of Commons
Dame Siobhain McDonaghLabour (Co-op)
31 October 2023
May contain errors — check source documents for definitive information.
This Bill aims to boost brain cancer research and care by setting a yearly target for glioblastoma patients to take part in clinical trials. It would also require training for medical oncologists in brain cancers, and require that licensed tumour drugs be trialled in brain tumour patients; it further strengthens neuro-oncology multidisciplinary teams and requires drug manufacturers to make licensed tumour drugs available for brain tumour trials.
The bill is at the 1st reading in the House of Commons. If it progresses, it will move to committee stage for scrutiny and then onward through Parliament.
Generated 21 February 2026
18 Oct 2023
The 2022-2023 session of Parliament has prorogued and this Bill will make no further progress.
No recorded votes for this bill yet.
